The future of implantable defibrillator and cardiac resynchronization therapy trials

Article

Abstract

Implantable cardioverter defibrillator (ICD) trials were initially limited to survivors of sudden death. The focus of defibrillator trials in the last decade has been in prophylactic implantation of the device in high risk populations for the prevention of sudden cardiac death. It is the contention in this review that the new focus for implantable defibrillator trials in 2008 and beyond will be on more selective and focused use of this therapy. This could be achieved by selecting ICD patients based on their pathophysiologic and genetic risk. Increasing effort will also be placed on using the device for prevention of spontaneous malignant ventricular tachyarrhythmias and the index clinical sudden death event. Finally, implantable defibrillators will be used in combination in a “hybrid” therapy approach. ICDs will be increasingly combined either with ventricular tachycardia ablation or ventricular fibrillation ablation using catheter techniques. With the addition of cardiac resynchronization therapy in these devices, new clinical trials that use cardiac resynchronization therapy as an early intervention in specific high risk heart failure populations and refinement of the CRT technique to improved optimal results are in progress. Finally, combining ICD devices and regenerative medicine approaches to myocardial replacement therapy are being explored.

Keywords

Sudden death Implantable defibrillators Heart failure Cardiac resynchronization therapy Therapy for arrhythmias Therapy for heart failure Reviews Myocardial infarction Clinical trials Genetics of arrhythmias Congenital heart disease Acquired heart disease 

References

  1. 1.
    Lee, D. S., Green, L. D., Liu, P. P., Dorian, P., Newman, D. M., Grant, F. C., et al. (2003). Effectiveness of implantable defibrillators for preventing arrhythmic events and death: A meta-analysis. Journal of the American College of Cardiology, 41, 1573–1582.PubMedCrossRefGoogle Scholar
  2. 2.
    Mirowski, M., Reid, P. R., Mower, M. M., Watkins, L., Gott, V. L., Schauble, J. F., et al. (1980). Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. The New England Journal of Medicine, 303(6), 322–324.PubMedGoogle Scholar
  3. 3.
    Saksena, S., Tullo, N. G., Krol, R. B., & Mauro, A. M. (1989). Initial clinical experience with endocardial defibrillation using an implantable cardioverter/defibrillator with a triple electrode system. Archives of Internal Medicine, 149, 2333–2339.PubMedCrossRefGoogle Scholar
  4. 4.
    Saksena, S., & PCD Investigator Group (1994). Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multiprogrammable implantable cardioverter–defibrillator implanted with or without thoracotomy: An international multicenter study. Journal of the American College of Cardiology, 23, 1521–1530.CrossRefGoogle Scholar
  5. 5.
    Saksena, S., De Groot, P., Krol, R. B., Raju, R., Matthew, P., & Mehra, R. (1993). Low-energy endocardial defibrillation using an axillary or a pectoral thoracic electrode location. Circulation, 88(6), 2655–2660.PubMedGoogle Scholar
  6. 6.
    The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators (1997). A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The New England Journal of Medicine, 337, 1576–1583.CrossRefGoogle Scholar
  7. 7.
    Kuck, K. H., Cappato, R., Siebels, J., & Rüppel, R. (2000). Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation, 102, 748–754.PubMedGoogle Scholar
  8. 8.
    Connolly, S. J., Gent, M., Roberts, R. S., Dorian, P., Roy, D., Sheldon, R. S., et al. (2000). Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation, 101, 1297–1302.PubMedGoogle Scholar
  9. 9.
    Moss, A. J., Hall, W. J., Cannom, D. S., Daubert, J. P., Higgins, S. L., Klein, H., et al. (1996). Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. The New England Journal of Medicine, 335, 1933–1940.PubMedCrossRefGoogle Scholar
  10. 10.
    Buxton, A. E., Lee, K. L., Fisher, J. D., Josephson, M. E., Prystowsky, E. N., & Hafley, G. (1999). A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. The New England Journal of Medicine, 341, 1882–1890.PubMedCrossRefGoogle Scholar
  11. 11.
    Moss, A. J., Zareba, W., Hall, W. J., Klein, H., Wilber, D. J., Cannom, D. S., et al. (2002). Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. The New England Journal of Medicine, 346, 877–883.PubMedCrossRefGoogle Scholar
  12. 12.
    Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., et al. (2005). Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. The New England Journal of Medicine, 352, 225–237.PubMedCrossRefGoogle Scholar
  13. 13.
    Higgins, S. L., Hummel, J. D., Niazi, I. K., Giudici, M. C., Worley, L. A., Saxon, J. P., et al. (2003). Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. Journal of the American College of Cardiology, 42, 1454–1459.PubMedCrossRefGoogle Scholar
  14. 14.
    Young, J. B., Abraham, W. T., Smith, A. L., Leon, A. R., Lieberman, R., Wilkoff, B., et al. (2003). Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators: Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure. Journal of the American Medical Association, 289, 2685–2694.PubMedCrossRefGoogle Scholar
  15. 15.
    Bristow, M. R., Saxon, L. A., Boehmer, J., Krueger, S., Kass, D. A., DeMarco, T., Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators, et al. (2004). Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. The New England Journal of Medicine, 350, 2140–2150.PubMedCrossRefGoogle Scholar
  16. 16.
    Abraham, W. T., Young, J. B., Leon, A. R., Adler, S., Bank, A. J., Hall, S. A., for the Multicenter InSync ICD II Study Group, et al. (2004). Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter–defibrillator, and mildly symptomatic chronic heart failure. Circulation, 110, 2864–2868.PubMedCrossRefGoogle Scholar
  17. 17.
    Schoenfeld, M. H., Compton, S. J., Mead, R. H., Weiss, D. N., Sherfesee, L., Englund, J., et al. (2004). Remote monitoring of implantable cardioverter defibrillators: A prospective analysis. Pacing and Clinical Electrophysiology, 27, 757–763.PubMedCrossRefGoogle Scholar
  18. 18.
    Joseph, G. K., Wilkoff, B. L., Dresing, T., Burkhardt, J., & Khaykin, Y. (2004). Remote interrogation and monitoring of implantable cardioverter defibrillators. Journal of Interventional Cardiac Electrophysiology, 11, 161–166.PubMedCrossRefGoogle Scholar
  19. 19.
    Lazarus, A. (2007). Remote, wireless, ambulatory monitoring of implantable pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy systems: Analysis of a worldwide database. Pacing and Clinical Electrophysiology, 30, S2–S12.PubMedCrossRefGoogle Scholar
  20. 20.
    Clark, R. A., Inglis, S. C., McAlister, F. A., Cleland, J. G., & Stewart, S. (2007). Telemonitoring or structured telephone support programmes for patients with chronic heart failure: Systematic review and meta-analysis. BMJ (Clinical Research Ed.), 334(7600), 910–911.CrossRefGoogle Scholar
  21. 21.
    The DAVID Trial Investigators (2002). Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator. Journal of the American Medical Association, 288(24), 3115–3123.CrossRefGoogle Scholar
  22. 22.
    Saksena, S. (2000). Implantable defibrillators in the third millennium: Increasingly relegated to a standby role? Journal of the American College of Cardiology, 36, 828–831.PubMedCrossRefGoogle Scholar
  23. 23.
    Ott, P., & Marcus, F. I. (2006). Electrocardiographic markers of sudden death. Cardiology Clinics, 24(3), 453–469.PubMedCrossRefGoogle Scholar
  24. 24.
    Gottipaty, V. K., Krelis, S. P., Spencer, E. P., White, B. G., Shusterman, V., Weiss, R., for the VEST investigators, et al. (1999). QRS dispersion, unlike QT dispersion, is a predictor of all cause mortality in patients with symptomatic congestive heart failure. Pacing and Clinical Electrophysiology, 22, 765.CrossRefGoogle Scholar
  25. 25.
    Gottipaty, V. K., Krelis, S. P., Lu, F., Spencer, E. P., Shusterman, V., Weiss, R., for the VEST investigators, et al. (1999). The resting electrocardiogram provides a sensitive and inexpensive marker of prognosis in patients with chronic congestive heart failure. Journal of the American College of Cardiology, 33, 145.Google Scholar
  26. 26.
    Goldstein, S., Fagerberg, B., Hjalmarson, A., Kjekshus, J., Waagstein, F., Wedel, H., MERIT-HF Study Group, et al. (2001). Metoprolol controlled release/extended release in patients with severe heart failure. Analysis of the experience in the MERIT-HF study. Journal of the American College of Cardiology, 38, 932–938.PubMedCrossRefGoogle Scholar
  27. 27.
    Gomes, J. A., Cain, M. E., Buxton, A. E., Josephson, M. E., Lee, K. L., & Hafley, G. E. (2001). Prediction of long-term outcomes by signal-averaged electrocardiography in patients with unsustained ventricular tachycardia, coronary artery disease, and left ventricular dysfunction. Circulation, 104, 436–441.PubMedCrossRefGoogle Scholar
  28. 28.
    Gold, M. R., Bloomfield, D. M., Anderson, K. P., El-Sherif, N. E., Wilber, D. J., Groh, W. J., et al. (2000). A comparison of T-wave alternans, signal averaged electrocardiography and programmed ventricular stimulation for arrhythmia risk stratification. Journal of the American College of Cardiology, 36, 2247–2253.PubMedCrossRefGoogle Scholar
  29. 29.
    Kearney, M. T., Fox, K. A. A., Lee, A. J., Brooksby, W. P., Shah, A. M., Flapan, A., et al. (2004). Predicting sudden death in patients with mild to moderate chronic heart failure. Heart (British Cardiac Society), 90, 1137–1143.Google Scholar
  30. 30.
    La Rovere, M. T., Pinna, G. D., Hohnloser, S. H., Marcus, F. I., Mortara, A., Nohara, R., ATRAMI Investigators, et al. (2001). Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: Implications for clinical trials. Circulation, 103, 2072–2077.PubMedGoogle Scholar
  31. 31.
    Malik, M., Camm, A. J., Janse, M. J., Julian, D. G., Frangin, G. A., & Schwartz, P. J. (2000). Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: A substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial). Journal of the American College of Cardiology, 35, 1263–1275.PubMedCrossRefGoogle Scholar
  32. 32.
    Bauer, A., Kontelhardt, J. W., Barthel, P., Schneider, R., Makikallio, T., Ulm, K., et al. (2006). Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: Cohort study. Lancet, 367, 1674–1681.PubMedCrossRefGoogle Scholar
  33. 33.
    Iesaka, Y., Nogami, A., Aonuma, K., Nitta, J., Chun, Y. H., Fujiwara, H., et al. (1990). Prognostic significance of sustained monomorphic ventricular tachycardia induced by programmed ventricular stimulation using up to triple extrastimuli in survivors of acute myocardial infarction. The American Journal of Cardiology, 65, 1057–1063.PubMedCrossRefGoogle Scholar
  34. 34.
    Costantini, O., Rosenbaum, D. S., Hohnloser, S. H., Kirk, M., Lerman, B., Baker II, J., ABCD Investigators, et al. (2006). The Alternans Before Cardioverter Defibrillator (ABCD) trial: A noninvasive strategy for primary prevention of sudden cardiac death using T-wave alternans. Circulation, 114, 2426, abstract.Google Scholar
  35. 35.
    Chow, T., Kereiakes, D. J., Onufer, J., Woelfel, A., Gursoy, S., Peterson, B. J., et al. (2007). Primary results from the Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients (MASTER I) trial. Circulation, 116, 2627–2633, abstract.CrossRefGoogle Scholar
  36. 36.
    Bloch-Thomsen, P. (2008). Long-term cardiac arrhythmias recorded by an insertable loop recorder in patients with reduced ejection fraction after acute myocardial infarction: The CARISMA Study. Journal of the American College of Cardiology, 51, 417–466, abstract.CrossRefGoogle Scholar
  37. 37.
    Steinbeck, G., Andresen, D., Senges, J., Hoffmann, E., Seidl, K., & Brachmann, J. (2004). Immediate Risk-Stratification Improves Survival (IRIS): Study protocol. Europace, 6, 392–399.PubMedCrossRefGoogle Scholar
  38. 38.
    Ottervanger, J., Misier, R., Zijlstra, F., Schalij, M., Wever, E., Jordaens, J., et al. (2006). Implantable defibrillator early after primary percutaneous intervention for ST-elevation myocardial infarction: Rationale and design of the Defibrillator After Primary Angioplasty (DAPA) Trial. American Heart Journal, 152(4), 636–640.PubMedCrossRefGoogle Scholar
  39. 39.
    Jouven, X., Desnos, M., Guerot, C., & Ducimetière, P. (1999). Predicting sudden death in the population. The Paris Prospective Study I. Circulation, 99, 1978–1983.PubMedGoogle Scholar
  40. 40.
    Sacher, F., Probst, V., Iesaka, Y., Jacon, P., Laborderie, J., Mizon-Gerard, F., et al. (2006). Outcome after implantation of a cardioverter–defibrillator in patients with Brugada syndrome: A multicenter study. Circulation, 114, 2317–2324.PubMedCrossRefGoogle Scholar
  41. 41.
    Sibling Concordance for Implantable Cardioverter–Defibrillator Therapies in Ischemic Cardiomyopathy (SIBFIB) study. ClinicalTrials.gov Identifier:NCT00498524.Google Scholar
  42. 42.
    Ventricular Tachyarrhythmia (VT) Storm: Gene Expression in Implantable Cardioverter Defibrillator (ICD) Patients With Electrical Storm study. ClinicalTrials.gov identifier:NCT00284453.Google Scholar
  43. 43.
    Sesti, F., Abbott, G. W., Wei, J., Murray, K. T., Saksena, S., Schwartz, P. J., et al. (2000). A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proceedings of the National Academy of Sciences of the United States of America, 97, 10613–10618.PubMedCrossRefGoogle Scholar
  44. 44.
    DISCOVERY: Diagnostic Data and Genetic Polymorphisms in ICD Patients trial. ClinicalTrials.gov identifier: NCT00478933.Google Scholar
  45. 45.
    Pacifico, A., Hohnloser, S. H., Williams, J. H., Tao, B., Saksena, S., Henry, P. D., for the d, l-Sotalol Implantable Cardioverter-Defibrillator Study Group, et al. (1999). Prevention of implantable-defibrillator shocks by pretreatment with sotalol. The New England Journal of Medicine, 340, 1855–1862.PubMedCrossRefGoogle Scholar
  46. 46.
    Singer, I., Al-Khalidi, H., Niazi, I., Tchou, P., Simmons, T., Henthorn, R., et al. (2004). Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. Journal of the American College of Cardiology, 43, 39–43.PubMedCrossRefGoogle Scholar
  47. 47.
    Marchlinski, F. E., Zado, E. S., Callans, D. J., Patel, V. V., Ashar, M. S., Hsia, H. H., et al. (2000). Hybrid therapy for ventricular arrhythmia management. Cardiology Clinics, 18, 391–406.PubMedCrossRefGoogle Scholar
  48. 48.
    Reddy, V. Y., Reynolds, M. R., Neuzil, P., Richardson, A. W., Taborsky, M., Jongnarangsin, K., et al. (2007). Prophylactic catheter ablation for the prevention of defibrillator therapy. The New England Journal of Medicine, 357, 2657–2665.PubMedCrossRefGoogle Scholar
  49. 49.
    SMS: Substrate Modification Study in Patients Getting an Implantable Cardioverter Defibrillator (ICD). ClinicalTrials.gov identifier: NCT00170287.Google Scholar
  50. 50.
    Saksena, S. (2006). Achieving global access to heart rhythm therapies in the next decade: A tangible goal. Journal of Interventional Cardiac Electrophysiology, 17, 163–168.PubMedCrossRefGoogle Scholar
  51. 51.
    Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death (SMART-ICD) Study. ClinicalTrials.gov Identifier: NCT00524862.Google Scholar
  52. 52.
    The Extracellular Matrix Marker of Arrhythmia Risk (EMMA) trial EMMA trial. ClinicalTrials.gov Identifier: NCT00376532.Google Scholar
  53. 53.
    CHARITY: Chagas cardiomyopathy bisoprolol intervention study: A randomized double-blind placebo force-titration controlled study with Bisoprolol in patients with chronic heart failure secondary to Chagas cardiomyopathy. ClinicalTrials.gov Identifier: NCT00323973.Google Scholar
  54. 54.
    The Evaluation of Arrhythmic Risk in Myotonic Dystrophy (RAMYD) Trial. ClinicalTrials.gov Identifier: NCT00127582.Google Scholar
  55. 55.
    Cleland, J. G. F., Daubert, J.-C., Erdmann, E., Freemantle, N., Gras, D., Kappenberger, L., the Cardiac Resynchronization—Heart Failure (CARE-HF) Study Investigators, et al. (2005). The effect of cardiac resynchronization on morbidity and mortality in heart failure. The New England Journal of Medicine, 352, 1539–1549.PubMedCrossRefGoogle Scholar
  56. 56.
    Lin, G., Rea, R. F., Hammill, S. C., Hayes, D. L., & Brady, P. A. (2008). Effect of cardiac resynchronisation therapy on occurrence of ventricular arrhythmia in patients with implantable cardioverter defibrillators undergoing upgrade to cardiac resynchronisation therapy devices. Heart (British Cardiac Society), 94, 186–190.Google Scholar
  57. 57.
    Moss, A. J., Brown, M. W., Cannom, D. S., Daubert, J. P., Estes, M., Foster, E., et al. (2005). Multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT): Design and clinical protocol. Annals of Noninvasive Electrocardiology, 10(4, Suppl), 34–43.PubMedCrossRefGoogle Scholar
  58. 58.
    The Reducing Decompensation Events Utilizing IntraCardiac Pressures in Patients with Chronic HF (REDUCE HF) trial. ClinicalTrials.gov Identifier: NCT00354159.Google Scholar
  59. 59.
    Saksena, S., Rahme, M., Viggrano, M., Dala, P., Matthew, P. (2008). Intraoperative optimization of cardiac resynchronization therapy using intracardiac echocardiography can enhance response and outcomes in refractory heart failure. Journal of the American College of Cardiology (in press).Google Scholar
  60. 60.
    Sogaard, P., Egeblad, H., Pedersen, A. K., Kim, W. Y., Kristensen, B. O., Hansen, P. S., et al. (2002). Sequential versus simultaneous biventricular resynchronization for severe heart failure: Evaluation by tissue Doppler imaging. Circulation, 106(16), 2078–2084.PubMedCrossRefGoogle Scholar
  61. 61.
    Myogenesis Heart Efficiency and Regeneration Trial (MYOHEART) study. ClinicalTrials.gov Identifier: NCT00054678.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Electrophysiology Research FoundationWarrenUSA

Personalised recommendations